Somewhat Positive Press Coverage Somewhat Unlikely to Impact MabVax Therapeutics Holdings (MBVX) Stock Price

Headlines about MabVax Therapeutics Holdings (NASDAQ:MBVX) have been trending somewhat positive on Tuesday, Accern reports. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. MabVax Therapeutics Holdings earned a coverage optimism score of 0.04 on Accern’s scale. Accern also assigned news articles about the company an impact score of 46.2084060682141 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

MabVax Therapeutics Holdings (MBVX) traded up 4.4124% during trading on Tuesday, reaching $0.7099. The company’s stock had a trading volume of 715,021 shares. The firm has a 50 day moving average of $0.57 and a 200 day moving average of $1.48. MabVax Therapeutics Holdings has a 52 week low of $0.43 and a 52 week high of $4.95. The stock’s market capitalization is $7.50 million.

MabVax Therapeutics Holdings (NASDAQ:MBVX) last issued its earnings results on Monday, August 14th. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.78). Analysts expect that MabVax Therapeutics Holdings will post ($2.91) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact MabVax Therapeutics Holdings (MBVX) Stock Price” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at

About MabVax Therapeutics Holdings

MabVax Therapeutics Holdings, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company has a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers.

Receive News & Ratings for MabVax Therapeutics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MabVax Therapeutics Holdings Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply